Navigation Links
MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
Date:4/22/2013

KENNESAW, Ga., April 22, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its common stock has been approved for listing on The NASDAQ Capital Market under the ticker symbol "MDXG."  Trading on NASDAQ is expected to commence on Thursday, April 25, 2013. Until such date, the Company's common stock will continue to be traded on OTC.BB under its current ticker symbol "MDXG".

"Listing on the NASDAQ exchange is an integral part of our plan to broaden and strengthen our shareholder base," said Parker H. "Pete" Petit, MiMedx Chairman and CEO.  "We expect the NASDAQ listing will increase the visibility of our stock, provide greater access to our stock and attract a broader range of investors to our stock, each of which is an essential element of our overall strategy to build shareholder value."

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary Purion® Process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 140,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement

This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to, the impact of the NASDAQ listing on the Company's stock price, shareholder base and shareholder value and the success of the Company's overall strategy to build shareholder value. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements are that the NASDAQ listing does not have the expected impact on the Company's stock price, shareholder base and shareholder value, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2012. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
2. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
3. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
4. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
5. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
6. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
7. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
8. MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference
9. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
10. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
11. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Delpor, Inc. ... $224K grant from the National Institute of Mental Health (NIMH) for the further advancement ... Delpor’s PROZOR technology and is expected to deliver therapeutic levels of olanzapine ...
(Date:2/24/2017)... PARSIPPANY, N.J. , Feb. 24, 2017 /PRNewswire/ ... botanicals and biotechnology are now the fastest growing ... the Specialty Actives in Personal Care: Multi-regional ... market research and management consulting firm Kline. ... using bioprocesses that make them more effective for ...
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ... immunotherapies, will host a Key Opinion Leader event to ... an oral and poster presentation at the upcoming 2017 ... The KOL event will be held in-person and via ... EST / 9:00 AM PST at the Lotte New ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
Breaking Biology Technology:
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/13/2017)... 13, 2017  RSA Conference -- RSA, a Dell ... designed to enhance fraud detection and investigation across ... RSA Fraud & Risk Intelligence Suite. The new ... additional insights from internal and external sources as ... their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
Breaking Biology News(10 mins):